期刊
CURRENT PHARMACEUTICAL DESIGN
卷 22, 期 7, 页码 870-878出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666151223102845
关键词
Therapeutic antibodies; hybridoma; fusion partner; B cells; EBV transformation; miR transformation
资金
- Ministry of Education and Science of the Russian Federation [14.604.21.0025/RFMEFI60414X0025]
- Pontificia Universidad Javeriana
- GALLY International Biomedical Research Consulting LLC, San Antonio, Texas, USA
- Russian Science Foundation (RSCF) [14-23-00160]
Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据